NCT00646503

Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B

A Single Arm, Multicenter, Open-label, 52-week, the Omnibus Extension Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B and Are HBV DNA PCR Negative at the End of Year 4 Treatment

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 150 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will explore efficacy and safety of Telbivudine in the fifth year of treatment.

Conditions

• Hepatitis B, Chronic

Interventions

Type	Name	Description
DRUG	Telbivudine	600 mg/day, oral telbivudine for 52 weeks

Timeline

• Start date: 2008-03-01
• Primary completion: 2009-09-01
• Completion: 2009-09-01
• First posted: 2008-03-28
• Last updated: 2017-06-22

Locations

1 site across 1 country: China